Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 10.

Yao, Qing; Wu, Ming; Zhou, Jie; Zhou, Meiyang; Chen, Dongping; Fu, Lili; Bian, Rongrong; Xing, Xiaohong; Sun, Lijun; Hu, Xiaohong; Li, Lin; Dai, Bing; Wüthrich, Rudolf P; Ma, Yiyi; Mei, Changlin (2017). Treatment of persistent gross hematuria with tranexamic acid in autosomal dominant polycystic kidney disease. Kidney & Blood Pressure Research, 42(1):156-164.

Wu, Ming; Gu, Junhui; Mei, Shuqin; Xu, Dechao; Jing, Ying; Yao, Qing; Chen, Meihan; Yang, Ming; Chen, Sixiu; Yang, Bo; Qi, Na; Hu, Huimin; Wüthrich, Rudolf P; Mei, Changlin (2016). Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor κB-induced inflammation. Nephrology, Dialysis, Transplantation, 31(11):1826-1834.

Wu, Ming; Chen, Meihan; Jing, Ying; Gu, Junhui; Mei, Shuqin; Yao, Qing; Zhou, Jie; Yang, Ming; Sun, Lijun; Wang, Wutao; Hu, Huimin; Wüthrich, Rudolf P; Mei, Changlin (2016). The C-terminal tail of polycystin-1 regulates complement factor B expression by signal transducer and activator of transcription 1. American Journal of Physiology. Renal, Fluid and Electrolyte Physiology, 310(11):1284-1294.

Gu, Junhui; Yang, Ming; Qi, Na; Mei, Shuqin; Chen, Jiejian; Song, Shuwei; Jing, Ying; Chen, Meihan; He, Liangliang; Sun, Lijun; Hu, Huimin; Li, Lin; Wüthrich, Rudolf P; Wu, Ming; Mei, Changlin (2016). Olmesartan prevents microalbuminuria in db/db diabetic mice through inhibition of angiotensin II/p38/SIRT1-induced podocyte apoptosis. Kidney & Blood Pressure Research, 41(6):848-864.

Wüthrich, R P; Kistler, A D; Rodriguez, Daniel; Kapoor, Sarika; Mei, Changlin (2015). Blood pressure control for polycystic kidney disease. In: Li, Xiaogang. Polycystic kidney disease. Brisbane: Codon Publications, Brisbane, Australia, 95-108.

Rodriguez, Daniel; Kapoor, Sarika; Edenhofer, Ilka; Segerer, Stephan; Riwanto, Meliana; Kipar, Anja; Yang, Ming; Mei, Changlin; Wüthrich, Rudolf P (2015). Inhibition of Sodium-GlucoseCotransporter 2 with dapagliflozin in Han: SPRD rats with polycystic kidney disease. Kidney & Blood Pressure Research, 40(6):638-647.

Wüthrich, Rudolf P; Mei, Changlin (2014). Pharmacological management of polycystic kidney disease. Expert Opinion on Pharmacotherapy, 15(8):1085-1095.

Chen, Dongping; Ma, Yiyi; Wang, Xueqi; Yu, Shengqiang; Li, Lin; Dai, Bing; Mao, Zhiguo; Sun, Lijun; Xu, Chenggang; Rong, Shu; Tang, Mengjun; Zhao, Hongbo; Liu, Hongchao; Serra, Andreas L; Graf, Nicole; Liu, Shiyuan; Wüthrich, Rudolf P; Mei, Changlin (2014). Clinical characteristics and disease predictors of a large Chinese cohort of patients with autosomal dominant polycystic kidney disease. PLoS ONE, 9(3):e92232.

Wang, Xueqi; Zhang, Suhua; Liu, Yang; Spichtig, Daniela; Kapoor, Sarika; Koepsell, Hermann; Mohebbi, Nilufar; Segerer, Stephan; Serra, Andreas L; Rodriguez, Daniel; Devuyst, Olivier; Mei, Changlin; Wüthrich, Rudolf P (2013). Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats. Kidney International, 84(5):962-968.

Wüthrich, Rudolf P; Mei, Changlin (2012). Aquaretic treatment in polycystic kidney disease. The New England Journal of Medicine, 367(25):2440-2442.

This list was generated on Tue Dec 12 14:06:46 2017 CET.